Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Working Capital Changes (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Other Working Capital Changes for 2 consecutive years, with $35.6 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 6450.46% to $35.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.5 million through Dec 2025, up 9626.01% year-over-year, with the annual reading at $35.5 million for FY2025, 9626.01% up from the prior year.
  • Other Working Capital Changes hit $35.6 million in Q4 2025 for Prelude Therapeutics, up from -$37000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $35.6 million in Q4 2025 to a low of -$3.9 million in Q3 2024.